The present invention relates to a technology for culturing Natural Killer cells (NK cells) applied to immunotherapy, and more particularly, a kit for adding to the serum-free immune cell culturing medium capable of effectively amplifying and activating immune cells that have been left for one day or longer after blood sampling or have become much weakened, while culturing NK cells to remarkably increase the portion of NK cells therein, compared with conventional immune cell-culturing methods, a method for culturing immune cells, a serum-free immune cell cultured medium obtained by the culturing method, and a cosmetic composition and a pharmaceutical composition comprising the cultured medium.

It is intended to provide a method for producing an NK cell-enriched blood preparation, which is low invasive and is capable of conveniently and rapidly growing NK cells, etc. in blood collected from an organism. The NK cells in blood are stimulated with NK cell growth-stimulating factors comprising an anti-CD16 antibody, OK432, an anti-CD137 antibody, and a cytokine. Then, the blood is cultured at a physiological cell temperature to produce an NK cell-enriched blood preparation.

Immunotherapeutic methods and compositions are contemplated where one or more neoepitopes and/or tumor associated antigens are produced in, or delivered to dendritic cells, and in which so modified dendritic cells are co-cultured with immune competent cells of a patient, preferably in the presence of stimulatory signals. Cells are then transfused to the patient that has preferably undergone immune checkpoint inhibition treatment.

The present invention pertains to extracellular vesicles (exosomes) that are produced by culturing tumor cells in the presence of various ligands or activators of innate immunity receptors and subsequently isolating and purifying the vesicles in the culture supernatant. The invention provides also pharmaceutical compositions comprising the inventive exosomes. The exosomes of the invention are provided as medicaments for example in the treatment of cancer diseases.

Disclosed are genetically modified porcine cells, tissues, organoids, and animals and methods of using the same for transplantation, and testing for xenoreactivity.

The present disclosure provides organoid co-cultures and methods of using such co-cultures. In particular, the present disclosure provides organoid-immune cell and organoid-bacterial cell co-cultures. The present disclosure further provides methods for testing therapeutic agents using the disclosed organoid co-cultures.

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. Embodiments of derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors in combination therapies.

The present invention relates to a potentiated T-cell modulator (TCM), with a potency of 10.sup.12 leucocytes/mm.sup.3, obtained from a dialysed extract of leucocytes from the spleen of Selachimorpha or sharks that contains peptides equal to or less than 10,000 Da, in powder form. The invention also relates to the use of the TCM to produce a medicine for treating diseases related to the regulation of immune response such as cancer or viral infections.

Provided is a method for preparing natural killer cell with high efficiency using irradiated peripheral blood mononuclear cells, more particularly to a method for proliferating highly activated NK cells using a combination of irradiated peripheral blood mononuclear cells (PBMCs) and a CD16 antibody and an anti-cancer cell therapeutic composition containing the natural killer cells (NK cells) prepared thereby. Further provided is a method for large-scale proliferation of activated NK cells with high efficiency using a combination of irradiated peripheral blood mononuclear cells (PBMCs) and a CD16 antibody without the use of cancer cells or genetically modified feeder cells having safety issues as feeder cells. The highly purified and highly cytotoxic NK cells proliferated in large quantities can be used as an active ingredient of a cancer immunotherapeutic composition.

The present invention relates to compositions that comprise monocytes that enhances the survival of stem cells and methods of transplanting such compositions for treating various conditions.